The project is part of the priority area of national interest SANATATE, having as main objective the creation of a core of high-level scientific and technological competence, at European standards, for the application of the process of transdifference in autologous cellular transplantation of diabetes, one of the major causes of morbidity and mortality in Romania and around the world. The strategic objectives of the project are: 1) Creating a Centre of Excellence – recognised nationally and internationally – for increasing the capacity of R & D-innovation and Romania’s participation in diabetes research at European level. 2) Integration of Romanian groups, coordinated by a foreign high-level researcher, into a strong research network, effective in the field of translational research of diabetes mellitus. 3) Creating a stimulating environment for the training of researchers and clinicians, including medical students, doctoral students, postdoctoral students, residents and other health specialists. 4) Developing technologies and tools in order to transfer liver cells to a phenotype manufacturer and insulin secretor. Prof. Ferber (Sheba Medical Ctr.) was the first to demonstrate the possibility of transdifference of adult liver cells into insulin secretor cells (IPCS). Under the leadership of Prof. Ferber the project will advance knowledge in the field, focusing in Romania on the behavior of liver cells from diabetic patients, in order to develop a potential curative procedure in the treatment of diabetes, of high priority in regenerative medicine. The Dia-Cure project suggests the use of pancreatic transcription factor (pTFs) to reprogram the diabetic patient’s liver cells into surrogate insulin-producing cells. The main objective of the project is to overcome the current limitations in cell transplant therapy for diabetic patients through an innovative transdifference/reprogramming approach designed to convert liver cells into β-like, insulin-producing cells.